Company Overview
Snapshot
Founded in April 2000 by Shuki Yeshurun, NanoPass Technologies operates with 11–50 employees. The company has raised $14.1M across 6 funding rounds from 6 investors. In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures, signaling continued growth and innovation in intradermal delivery technology.
Business overview
NanoPass Technologies is at the forefront of healthcare innovation, specializing in intradermal delivery solutions. The company develops proprietary technology, including its MicronJetTM intradermal delivery product platform, to enhance therapeutic and medical aesthetic procedures. NanoPass Technologies serves the health tech and life sciences sectors, focusing on drug delivery and medical devices to provide precise, safe, and efficient medical solutions.
Strategic signal
In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures. This funding underscores investor confidence in the company's pioneering intradermal delivery technology and its potential to advance medical and aesthetic treatments, positioning NanoPass for further product development and market expansion.
Log in to access full profile ›Company Intelligence Q&A
- What is NanoPass Technologies' core product?
- NanoPass Technologies' core product is the MicronJetTM intradermal delivery platform, which utilizes MEMS Technology for precise and efficient delivery of therapeutics and medical aesthetics.
- When was NanoPass Technologies founded?
- NanoPass Technologies was founded in April 2000.
- Which investor participated in NanoPass Technologies' July 2024 funding round?
- In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures, as reported by PR Newswire.
- What was a significant partnership for NanoPass Technologies in 2012?
- In November 2012, NanoPass Technologies granted a commercial license to Janssen Pharmaceuticals, Inc., for the use of its MicronJet device.
- What was a key development for NanoPass Technologies in early 2022?
- In February 2022, NanoPass's intradermal injection platform was proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose, as reported by the Chinese Institute of Medical Biology.